Fran calvá ⭑
Region: AR
Thursday 29 May 2025 01:33:18 GMT
169416
39226
123
7827
Music
Download
Comments
𝒷𝓇𝒾𝓈𝒶 🥢 :
que bella que sos no llores nunca por un hombre
2025-05-29 01:56:07
170
Thiagoo✌🏻 :
Lo bueno nunca se cuenta
2025-05-29 02:12:00
49
Alberto.sisisi :
Voy a deslizar, pero no voy a olvidar tus ojos 🫵🏽
2025-05-29 20:56:22
14
JULI🪽 :
Fran sos demasiado preciosa dios mío 😭
2025-05-30 01:22:52
5
M.Ángel 🍞 :
la mejor canción de todo el álbum
2025-05-29 10:24:47
7
Mkevaii :
Su mirada es lo que hace que el video nunca pare 😔❤️❤️
2025-05-29 01:42:20
4
Carl :
Amo la mirada del final 😻🥹 !
2025-05-29 23:38:13
4
Martin Alan :
que si, que vos irresistible y yo arrestable
2025-05-29 16:58:09
2
gg.miiaa :
que linda🩷
2025-05-29 02:40:53
1
melig718 :
Que me costaba
2025-05-29 03:26:30
1
York villena :
Q buen álbum ese!
2025-05-29 05:14:17
1
Alexia 🍒 :
sos hermosa mi reina🥹
2025-05-29 01:42:25
1
_danol🎰🎸 :
muy bien te salen las gesticulaciones 👏
2025-05-29 01:45:27
1
جوسلين :
Que bonitaaaa!!!
2025-05-29 17:22:30
1
Alexander🧑🏾🦱 :
Comentando hasta que me responda😩
2025-05-29 03:23:27
2
samirodrigueezz :
No podes ser tan linda😍
2025-05-29 05:06:17
1
Gerson • Siguiendo :
segundo
2025-05-29 02:13:49
1
Nelson Arevalo :
primero
2025-05-29 01:36:41
1
manuelrodriguez62599 :
Ese álbum no tiene skips
2025-05-29 02:13:24
1
𝒷𝓇𝒾𝓈𝒶 🥢 :
sos toda hermosaaaaaa
2025-05-29 05:07:11
1
heber gelvis :
Tiene una skin legendaria 🗿
2025-05-29 02:28:13
1
brayanTorres4822 :
Que linda
2025-05-29 04:43:50
0
Tαтι :
Sos divinaaaa, igual a afra saracoglu 😍
2025-05-31 06:27:17
0
ariel.nxx7 :
x dios q mujer 😭😍😍😍
2025-05-29 12:23:01
0
To see more videos from user @francaalv, please go to the Tikwm
homepage.
![Replying to @Slamuri #saynoto7oh Products containing the psychoactive botanical, Mitragyna speciosa, have transformed from simple leaf powders into an array of products, falling under the broad umbrella of ‘kratom’. [1, 2] Whole-leaf products contain consistent concentrations of kratom’s major alkaloid, mitragynine, and its metabolite 7-hydroxymitragynine; even among extracts, alkaloid concentrations often remain within self-adopted industry norms, with 7-hydroxymitragynine between 1 and 2% of the total content, or below the lower limit of quantification [3-5]. A highly selective partial mu opioid receptor (MOR) agonist, 7-hydroxymitragynine has binding affinity 14–22 times greater than morphine [6]. Although mitragynine has lower abuse potential and relative safety compared to drugs of abuse, 7-hydroxymitragynine dose-dependently substitutes for morphine [7-11]. However, some manufacturers have begun marketing novel semi-synthetic products with varying routes of administration (e.g. sublingual tablets, nasal sprays) containing 14–25 mg 7-hydroxymitragynine per labeled dose, often with brand names alluding to narcotics. These newly marketed products may contain up to 98% 7-hydroxymitragynine, together with other kratom alkaloids. Concerningly, some product formulations circumvent first-pass metabolism, increasing bioavailability. To date, 7-hydroxymitragynine product marketing fails to distinguish itself from kratom. Kratom-naïve consumers purchasing 7-hydroxymitragynine products may erroneously believe that they are relatively safe ‘natural’ products similar or identical to kratom products that have been used in the United States for at least two decades. Consumers of these novel products are unwittingly exposing themselves to high-dose, MOR-binding formulations that have never undergone human or animal testing. Apart from toxicity risks from acute exposure, chronic 7-hydroxymitragynine product use could result in opioid-like physical dependence and possibly addiction. Scale and severity may be distinct from kratom leaf-based and extract products, which have not produced widespread severe addiction, but rather mild–moderate physical dependence [12-14]. As forensic laboratories use mitragynine as a surrogate marker for kratom use, 7-hydroxymitragynine-related fatalities would incorrectly implicate kratom, as the presence of mitragynine in these products arises from incomplete conversion of mitragynine into 7-hydroxymitragynine [15]. Currently, 7-hydroxymitragynine products contain trace amounts of mitragynine and ‘new’ chemicals yet to be identified. The safety of these unknown chemicals, and of 7-hydroxymitragynine at high doses, has not been evaluated in living subjects. Accordingly, they pose an eminent public health concern until they have been identified and proven to be safe. The policy implications of semi-synthetic 7-hydroxymitraynine products are unknown, but adverse events or fatalities resulting from 7-hydroxymitragynine products could pose complications to the regulation of a growing kratom industry. Kratom is now used by 10–15 million US adults. Decisions regarding kratom scheduling and regulation are liable to become confused if policymakers can or will not differentiate between kratom and high-potency 7-hydroxymitragynine products synthesized in unregulated or makeshift laboratories. To be clear: equating 7-hdyroxymitragynine products to kratom is analogous to equating synthetic cannabinoids to unaltered cannabis or hemp. Although not all organic kratom products are equal, they have not emerged as a net detriment to public health, and they remain unscheduled at the federal level. Novel semi-synthetic 7-hydroxymitragynine products pose public health risks due to the unknown chemical constituents and the known pharmacology of 7-hydroxymitragynine. Clinicians must screen patients for their use and policymakers must distinguish between kratom and 7-hydroxymitragynine. #7oh #7hydroxymitragynine #kraytum #kr8tom](/video/cover/7518140023510699295.webp)
